[Federal Register Volume 82, Number 232 (Tuesday, December 5, 2017)]
[Notices]
[Pages 57455-57457]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-26150]



[[Page 57455]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Statement of Organization, Functions, and Delegations of 
Authority

    Part C (Centers for Disease Control and Prevention) of the 
Statement of Organization, Functions, and Delegations of Authority of 
the Department of Health and Human Services (45 FR 67772-76, dated 
October 14, 1980, and corrected at 45 FR 69296, October 20, 1980, as 
amended most recently at 81 FR 84583-84591, dated November 23, 2016) is 
amended to reflect the reorganization of the Division of Viral 
Diseases, National Center for Immunization and Respiratory Diseases, 
Office of Infectious Disease, Centers for Disease Control and 
Prevention.
    Section C-B, Organization and Functions, is hereby amended as 
follows:
    Delete and replace the title and the mission and function 
statements for the Division of Viral Disease (CVGE) and insert the 
following:
    Division of Viral Disease (CVGE). The Division of Viral Diseases 
(DVD) prevents disease, disability, and death through immunization and 
by control of respiratory, enteric, and related viral diseases. In 
carrying out this mission, the DVD: (1) Conducts surveillance and 
related activities; supports and provides technical assistance to state 
and local health departments to conduct surveillance and related 
activities to monitor the impact of vaccination and other prevention 
programs; and determine patterns of infection and disease; (2) conducts 
epidemiologic and laboratory studies to define patterns of, and risk 
factors for, infection, disease, and disease burden; estimates vaccine 
effectiveness, determines cost effectiveness of vaccines, and evaluates 
other aspects of immunization practices; identifies and evaluates non-
vaccine prevention strategies; and provides epidemiological and 
laboratory expertise to other Nation Centers (NCs), collaborators, and 
partners on vaccine and other prevention strategies; (3) provides 
consultation on viral vaccine preventable, respiratory, and enteric 
diseases, and the use of vaccines and other measures to prevent 
infections; (4) provides consultation and support and/or participates 
in investigations of national and international outbreaks of viral 
vaccine preventable and other respiratory and enteric viral diseases, 
and recommends appropriate control measures; (5) provides scientific 
leadership and advice, analyzes available data, and develops science-
based statements for viral vaccines to the Advisory Committee on 
Immunization Practices (ACIP) and other groups to support the 
development and evaluation of immunization practices and policies 
domestically and internationally; (6) provides laboratory support for 
surveillance and epidemiologic studies and maintains reference/
diagnostic services and expertise; (7) conducts studies of immunology 
and pathogenesis of disease and the biology, biochemical, genetic and 
antigenic characteristics of the agents; (8) develops, evaluates, and 
improves diagnostic methods and reagents, and transfers assays and 
techniques to other public health laboratories; (9) facilitates and 
participates in the development and evaluation of antiviral compounds, 
vaccines, and vaccination programs; (10) provides and supports public 
health training; (11) responds to and assists internal and external 
partners on other public health problems of national and international 
significance, as needed; (12) provides technical support to state 
immunization programs for all aspects of vaccine-preventable diseases 
and their vaccines; (13) provides leadership in vaccine science; and 
(14) supports CDC's Immunization Safety Office in vaccine safety risk 
assessment and leadership in vaccine safety risk management.
    Office of the Director (CVGE1). (1) Manages, directs, and 
coordinates the activities of the division; (2) provides leadership and 
guidance in policy formulation, program planning and development, 
program management, and operations of the division; (3) identifies 
needs and resources for ongoing and new initiatives and assigns 
responsibilities for their development; (4) prepares, reviews, and 
coordinates informational, scientific, and programmatic documents; (5) 
oversees the division's activities and expenditures; (6) assures the 
overall quality of the science conducted by the division; (7) provides 
overall guidance and direction for the division's surveillance, 
research, and other scientific and immunization activities; (8) 
provides overall guidance and direction for division's epidemiologic, 
laboratory, and outbreak response capacity and activities; (9) oversees 
and facilitates the division's scientific support to other groups 
within CDC, the national and international healthcare, and public 
health communities regarding viral respiratory and enteric diseases and 
viral immunization programs; (10) guides and facilitates efficient 
coordination and cooperation for administrative, programmatic, and 
scientific activities within the division and with other groups inside 
and outside of CDC; and (11) provides division leadership, expertise, 
and technical collaboration for the application of statistics, 
economics, operations research, geography, other quantitative sciences, 
and data management to prevent disease, disability and death through 
immunization and control of respiratory, enteric, and related viral 
diseases.
    Analysis and Data Management Activity (CVGE12). (1) Coordinates 
quantitative science and data management planning, policy development, 
and project monitoring and evaluation; (2) designs and develops 
statistical, economic, cost, resource allocation, geospatial and data 
management strategies, models, and methodologies in the public health 
arena; and (3) collaborates with scientists, program experts, and 
senior public health officials throughout the division to implement 
these strategies, models, and methodologies in support of respiratory, 
enteric and related viral diseases surveillance and prevention studies, 
prevention resource allocation issues, and prevention program 
activities.
    Respiratory Viruses Branch (CVGEB). (1) Conducts surveillance, 
laboratory assistance, and related activities, and supports and 
provides technical assistance to state and local health departments to 
conduct surveillance and related activities to monitor the impact of 
prevention programs, and determine patterns of infection and disease; 
(2) conducts and provides laboratory support and expertise for 
epidemiologic and laboratory studies to define patterns of and risk 
factors for infection, disease, and disease burden; (3) provides 
epidemiology and laboratory consultation and support and/or 
participates in investigations of national and international outbreaks 
of viral respiratory diseases, and recommends appropriate control 
measures; (4) provides scientific, both epidemiologic and laboratory, 
leadership and advice; (5) analyzes available data, and develops 
science-based statements for potential respiratory viral vaccines to 
the ACIP and other groups to support the development and evaluation of 
immunization practices and policies in the U.S and internationally; (6) 
provides and supports public health training; (7) responds to and 
assists internal and

[[Page 57456]]

external partners on other public health problems of national and 
international significance, as needed; (8) provides laboratory support 
for surveillance and epidemiologic studies and maintains reference/
diagnostic services and expertise; (9) conducts studies of immunology 
and pathogenesis of disease and the biology, biochemical, genetic, and 
antigenic characteristics of the agents; (10) develops, evaluates, and 
improves diagnostic methods and reagents, and transfers assays and 
techniques to other public health laboratories and provides and 
supports laboratory training; (11) facilitates and participates in the 
development and evaluation of antiviral compounds, vaccines, and 
vaccination programs; and (12) responds to and assists internal and 
external partners on other public health problems of national and 
international significance as needed.
    Polio and Picornavirus Laboratory Branch (CVGEC). (1) Provides 
laboratory assistance, technical expertise and support for surveillance 
and related activities to monitor impact of vaccination and other 
prevention programs, and determine patterns of infection and disease; 
(2) provides laboratory support and technical expertise for 
epidemiologic and laboratory studies to define patterns and risk 
factors for infection, disease, and disease burden; (3) studies 
vaccine-related issues; (4) identifies and evaluate non-vaccine 
prevention strategies; (5) provides laboratory consultation and 
technical expertise regarding use of vaccines and other measures to 
prevent infections to other NCs, collaborators, and partners; (6) 
provides laboratory consultation and support and/or participates in 
investigations of national and international outbreaks of viral vaccine 
preventable and other respiratory and enteric viral diseases; (7) 
provides laboratory leadership and technical expertise to develop 
science-based statements to Global Polio Eradication Initiative, the 
ACIP, and other groups to support the development and evaluation of 
immunization practices and policies in the U.S and internationally; (8) 
provides epidemiology and laboratory consultation and support and/or 
participates in investigations of national and international outbreaks 
of viral respiratory diseases, and recommends appropriate control 
measures; (9) provides scientific, both epidemiologic and laboratory, 
leadership and advice; (10) provides laboratory support for 
surveillance and epidemiologic studies and maintains reference/
diagnostic services and expertise; (11) conducts studies of immunology 
and pathogenesis of disease and the biology, biochemical, genetic, and 
antigenic characteristics of the agents; (12) develops, evaluates, and 
improves diagnostic methods and reagents, transfers assays and 
techniques to national and international public health laboratories, 
and provides and supports training for laboratorians; (13) facilitates 
and participates in the development and evaluation of antiviral 
compounds, vaccines, and vaccination programs; (14) responds to and 
assists internal and external partners on other public health problems 
of national and international significance as needed; and (15) serves 
as the National Reference Laboratory (poliovirus and enteroviruses), 
World Health Organization (WHO) Collaborating Center for Poliovirus and 
Enteroviruses Virus Reference and Research, and WHO Global Specialized 
Polio Reference Laboratory.
    Viral Vaccine Preventable Diseases Branch (CVGED). (1) Conducts 
surveillance, provides laboratory assistance, technical expertise, and 
support for surveillance and related activities to monitor the impact 
of vaccination on the prevention of viral disease and to determine 
patterns of infection and disease; (2) conducts epidemiologic and 
laboratory studies to define patterns of and risk factors for 
infection, disease, and disease burden; (3) estimates vaccine 
effectiveness, evaluates other aspects of immunization practices; (4) 
identifies and evaluates non-vaccine prevention strategies; (5) 
provides epidemiological and laboratory expertise and technical support 
to other NCs, collaborators, and partners across center working groups 
on vaccines and other prevention strategies; (6) supports the 
development of vaccine practices and policies by providing consultation 
and epidemiologic and laboratory expertise to other federal agencies, 
state health departments, ministries of health, WHO, PAHO, private 
industry, academia and other governmental organizations on viral 
vaccine preventable diseases, and on the use of vaccines and other 
measures to prevent infections; (7) provides laboratory consultation 
and support and/or participates in investigations of national and 
international outbreaks of viral vaccine preventable diseases and 
recommends appropriate control measures; (8) assists internal and 
external partners on other public health problems of national and 
international significance; (9) provides scientific leadership and 
advice, analyzes available data, and develops science-based statements 
for viral vaccines to the ACIP and other groups to support the 
development and evaluation of immunization practices and policies in 
the U.S and internationally; (10) responsible for human papilloma virus 
(HPV), measles, mumps, rubella (MMR), domestic polio, zoster, and 
varicella vaccine policy in the United States by working with ACIP; 
(11) provides and supports public health training; (12) responds to 
public inquires and prepares communication materials; (13) works with 
health economists to determine cost effectiveness of vaccination 
strategies; (14) provides laboratory support for surveillance and 
epidemiologic studies and maintains reference and diagnostic services 
and expertise; (15) assists in investigation of adverse events 
following vaccination; (16) conducts studies of immunology and 
pathogenesis of disease and the biological, biochemical, genetic, and 
antigenic characteristics of viral agents; (17) develops, evaluates, 
and improves diagnostic methods and reagents; (17) transfers assays and 
techniques to other public health laboratories; (18) provides and 
supports laboratory training; (19) serves as the National Reference 
Laboratory for MMR, and varicella zoster virus and the PAHO Regional 
and WHO Global Specialized Laboratory for measles and rubella; and (20) 
works closely with the laboratory that handles HPV to define and 
conduct epidemiologic investigations.
    Viral Gastroenteritis Branch (CVGEE) (1) Provides epidemiologic and 
laboratory assistance studies and related activities to better 
understand the evolution, (molecular) epidemiology and immunity of 
rotavirus, norovirus and other gastroenteritis viruses; (2) provides 
consultation on the safety and impact of rotavirus vaccination and 
other prevention programs (rotavirus, norovirus); (3) provides 
consultation and technical assistance to state and local health 
departments to monitor the burden of disease and epidemiology of 
gastroenteritis virus infections (rotavirus, norovirus); (4) provides 
consultation and support on the research and development of new 
rotavirus vaccines and other prevention technologies; (5) provides 
consultation and support and/or participates in investigations of 
national and international outbreaks of viral vaccine preventable and 
other enteric viral diseases, and recommends appropriate control 
measures; (6) provides scientific leadership and advice, analyzes 
available data, and develops science-based statements for rotavirus 
vaccines to the ACIP and other groups to support the development and 
evaluation of

[[Page 57457]]

immunization practices and policies in the U.S and internationally; (7) 
provides and supports public health training; (8) responds to and 
assists internal and external partners on other public health problems 
of national and international significance, as needed; (9) serves as 
the National Reference Laboratory (rotavirus and norovirus) and other 
agents of viral gastroenteritis; and (10) serves as the WHO Global 
Reference Center for Rotavirus and other agents of viral 
gastroenteritis.

Sherri Berger,
Chief Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2017-26150 Filed 12-4-17; 8:45 am]
 BILLING CODE 4160-18-P